Clinical trials: Ischemic Brain
Ischemic Stroke
Effectiveness and Safety Trial of a New Ischemic Stroke Treatment Within 24 Hours From Stroke Onset (NEST-2)
The purpose of this pivotal study is to demonstrate safety and effectiveness of the NeuroThera® Laser System (referred to hereafter as NTS) in the treatment of Subjects diagnosed with acute ischemic stroke.
- Trial name
- NCT00419705
- Testing
- NeuroThera® Laser System
- Where
- 58 sites in United States, Germany and 2 more
- Volunteers
- 660 people
- Sponsor
- PhotoThera, Inc
Cardiovascular Event, Parkinson Disease
Cardiovascular Events in Parkinson's Disease Patients
Cardiovascular (CV) disease is a common comorbidity of Parkinson's disease (PD). The background incidence rate of CV events in a levodopa-treated PD population was assessed to better understand these comorbidities in the PD…
- Trial name
- NCT01545856
- Testing
- levodopa
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Stroke, Ischemic Stroke
Study of ALD-401 Via Intracarotid Infusion in Ischemic Stroke Subjects
The purpose of this study is to demonstrate the safety of the delivery of ALD-401 by intracarotid infusion and to assess efficacy of treatment in subjects who have had unilateral, predominately cortical, ischemic strokes in the…
- Conditions
- Stroke, Ischemic Stroke, Stroke in Middle Cerebral Artery (MCA)
- Trial name
- NCT01273337
- Testing
- ALD-401
- Where
- 9 sites in United States
- Volunteers
- 100 people
- Sponsor
- Aldagen
Atherosclerotic Cardiovascular Disease
In Silico Study Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Patients With Established Cardiovascular Disease
Study CKJX839B1FR01 in an In silico trial to predict the efficacy of Inclisiran therapy on major adverse cardiovascular events (MACE) and cardiovascular (CV) death in virtual patients with atherosclerotic cardiovascular disease…
- Trial name
- SIRIUS (NCT05974345)
- Testing
- Inclisiran sodium, Ezetimibe, Evolocumab
- Where
- France
- Volunteers
- 204,691 people
- Sponsor
- Novartis Pharmaceuticals
Acute Ischemic Stroke
PREVAIL: PREvention of VTE After Acute Ischemic Stroke With LMWH Enoxaparin ( - VTE: Venous Thromboembolism - LMWH: Low Molecular Weight Heparin)
Primary objective: To demonstrate superiority of enoxaparin 40 mg sc qd in the prevention of VTE compared to UFH (unfractionated heparin) 5000 U sc q12 hours given for 10 ± 4 days following acute ischemic stroke.
- Trial name
- NCT00077805
- Testing
- Enoxaparin sodium
- Where
- 15 sites in United States, Australia and 13 more
- Sponsor
- Sanofi
Acute Ischemic Stroke, Cerebral Edema
The Tolerability, Safety, and PK Characteristics of SIM1910-09 in Healthy Chinese Volunteers
This is a single-center, randomized, double-blind, placebo-controlled Phase I clinical study to evaluate the tolerability, safety, and pharmacokinetic characteristics of SIM1910-09 for injection after single/multiple dosing in…
- Trial name
- NCT05200728
- Testing
- SIM1910-09
- Where
- China
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Acute Ischemic Stroke
FIrst-Pass Reperfusion With the NeVa Stent-Retriever Trial
This study is designed to compare the safety, performance and efficacy of blood clot (thrombus) removal in subjects presenting with acute ischemic stroke with the NeVa versus the Solitaire stent retrievers.
- Trial name
- FIRST (NCT04072367)
- Testing
- NeVa Stent Retrievers, Solitaire Stent Retrievers
- Sponsor
- Vesalio
Epilepsy, Dravet Syndrome
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Participants With Developmental and/or Epileptic Encephalopathies
The purpose of this study is to investigate the effect on the frequency of all seizures (convulsive and drop) in participants treated with TAK-935 compared to placebo.
- Conditions
- Epilepsy, Dravet Syndrome, Lennox-Gastaut Syndrome
- Trial name
- ELEKTRA (NCT03650452)
- Testing
- TAK-935
- Where
- 44 sites in United States, Australia and 6 more
- Volunteers
- 141 people
- Sponsor
- Takeda
Stroke
Temporal Trends of Thrombolysis Treatment in Chinese Acute Ischemic Stroke (AIS) Patients From 2007-2017: Analysis of China National Stroke Registry (CNSR) I, II, and III; CTP-Draft Review Performed;
The present study is to be conducted based on the AIS patient data collected from CNSR I, II, and III. The primary objectives are: To investigate the temporal changes in the proportion of intravenous recombinant plasminogen…
- Trial name
- NCT04290494
- Testing
- IV rtPA (intravenous recombinant plasminogen activator)
- Where
- China
- Volunteers
- 42,188 people
- Sponsor
- Boehringer Ingelheim
Ischemic Stroke
The Safety and Efficacy of Cerebrolysin in Patients With Acute Ischemic Stroke
The study investigated the clinical efficacy and safety of a 10-day course of therapy with daily intravenous administration of 30mL Cerebrolysin based on a comparison with Placebo in patients with acute ischemic stroke.
- Trial name
- CASTA (NCT00868283)
- Testing
- Cerebrolysin, 0.9% Saline Solution
- Where
- 49 sites in China, Hong Kong and 1 more
- Volunteers
- 1,071 people
- Sponsor
- Ever Neuro Pharma GmbH
Ischemic Stroke
Navigated Transcranial Magnetic Stimulation in Monitoring Stroke Recovery
The past 10 years of research in persons more than 6 months post stroke have shown certain types of rehabilitation can help "re-wire" the brain.
- Trial name
- NCT01005394
- Testing
- Navigated TMS examination
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Nexstim Ltd
Ischemic Stroke
Implant for Augmentation of Cerebral Blood Flow Trial, Effectiveness and Safety in a 24 Hour Window
The primary objective of the study is to assess the safety and effectiveness of SPG stimulation with the ISS in patients with an acute ischemic stroke in the anterior circulation initiated within 24 hours from stroke onset.
- Trial name
- ImpACT-24B (NCT00826059)
- Testing
- Active Sphenopalatine Ganglion (SPG) Stimulation
- Where
- 73 sites in United States, Canada and 16 more
- Volunteers
- 1,078 people
- Sponsor
- BrainsGate
Stroke
A Study in Chinese Patients to Compare How Tenecteplase and Alteplase Given After a Stroke Improve Recovering of Physical Activity
This study is open to Chinese adults who had an ischaemic stroke, which means that blood vessels in the brain are blocked. To resolve blood clots, people in the study get either tenecteplase or alteplase within 4 hours and 30…
- Trial name
- ORIGINAL (NCT04915729)
- Testing
- tenecteplase, alteplase
- Where
- 55 sites in China
- Volunteers
- 1,489 people
- Sponsor
- Boehringer Ingelheim
Heart Attack and Stroke
Emergency Call for Heart Attack and Stroke (ECHAS) - ECHAS One Study
ECHAS One will test the use of a smartphone app to assist patients to decide if it is necessary to call for emergency care with symptoms that could represent a heart attack or stroke.
- Trial name
- ECHAS (NCT05230069)
- Testing
- Interview
- Volunteers
- 200 people
- Sponsor
- Emergency Call for Heart Attack and Stroke (ECHAS)
Ischemic Stroke, Tandem Occlusion
Safety, Tolerability and Efficacy of Adjunctive TBO-309 in Reperfusion for Stroke With Tandem Occlusion
Co-STAR is a multicenter, prospective, open-label, Bayesian Optimal Phase 2 (BOP2) trial that aims to assess the safety and efficacy of adjunctive intravenous TBO-309 in Acute Ischaemic Stroke (AIS) patients with tandem occlusion…
- Trial name
- Co-STARS (NCT06813651)
- Testing
- TBO-309: 60 mg, TBO-309: 120 mg, TBO-309: 30 mg
- Where
- 2 sites in Australia
- Volunteers
- 78 people
- Sponsor
- ThromBio Pty. Ltd.
Cerebral Infarction
Cilostazol in Acute Ischemic Stroke Treatment (CAIST)
The purpose of this study is to study efficacy and safety of cilostazol use in patients with acute ischemic stroke.
- Trial name
- NCT00272454
- Testing
- Cilostazol, Aspirin
- Where
- 12 sites in South Korea
- Volunteers
- 468 people
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
Patent Foramen Ovale, Cryptogenic Stroke
Safety and Efficacy of Cera™ Patent Foramen Ovale Occluders.
To evaluate the performance of Cera™ patent foramen ovale occluders developed by Lifetech Scientific (Shenzhen) Co., LTD;
- Trial name
- NCT05774288
- Testing
- Cera™ patent foramen ovale occluders, Another patent foramen ovale occluders
- Where
- 14 sites in China
- Volunteers
- 244 people
- Sponsor
- Lifetech Scientific (Shenzhen) Co., Ltd.
Ischemic Stroke
ThrombX Retriever for Acute Ischemic Stroke Trial
This trial is designed to assess the safety and effectiveness of the ThrombX Retriever.
- Trial name
- TRAC (NCT05270122)
- Testing
- Mechanical thrombectomy with ThrombX Retriever
- Volunteers
- 200 people
- Sponsor
- ThrombX Medical
Ischemic Stroke
Augmenting Cerebral Blood Flow to Preserve the Penumbra Trial
The primary objective of the study is to demonstrate that SPG (Sphenopalatine Ganglion) stimulation started within 6 hours from stroke onset slows the expansion of the infarct core volume in acute ischemic stroke.
- Trial name
- ImpACT-P (NCT04014621)
- Testing
- SPG stimulation
- Where
- 4 sites in Georgia
- Volunteers
- 100 people
- Sponsor
- BrainsGate
Cerebral Infarction
Chinese Assessment for Vinpocetine In Neurology
Trial Title：The treatment of Vinpocetine（Cavinton）in patients with cerebral infarction, an open, randomized, multi-center control study 1.
- Trial name
- CAVIN (NCT01400035)
- Where
- China
- Volunteers
- 610 people
- Sponsor
- Shanghai Rxmidas Pharmaceuticals Co. Ltd.